drugset / Trial / NCT02183584

Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers

NCT02183584

Phase 1 Completed 16 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Investigation of the bioavailability of linagliptin after concomitant multiple oral administration of 5 mg linagliptin tablets and 600 mg rifampicin (Treatment A) in comparison to multiple oral administration of 5 mg linagliptin tablets given alone (Treatment B)

Timeline

Start
2009-09
Primary completion
2009-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.